Ann Clin Nutr Metab.  2023 Dec;15(3):88-96. 10.15747/ACNM.2023.15.3.88.

Multi-biomarker approach to metabolic syndrome and associated diseases in Turkey: a cross sectional study

• Mamur SC
• Colak O
• Metintas S
• Arikan I
• Kara M

• KMID: 2548775
• DOI: http://doi.org/10.15747/ACNM.2023.15.3.88

Abstract

Purpose
Biomarker for cardiovascular diseases (CVDs) are important in the clinical monitoring of individuals with metabolic syndrome (MetS). The use of these biomarkers in combination may be predictive of CVDs. This study aimed to demonstrate the ability of multiple biomarkers to predict MetS, diabetes mellitus (DM), and CVDs. The use of multiple biomarkers instead of a single biomarker may be more useful in early diagnosis. We investigated the use of a multi-biomarker approach in MetS and associated diseases.
Methods
The study was performed by selecting control (n=30), MetS (n=30), MetS+DM (n=30), and MetS+CVD (n=30) groups from data of the Eskisehir Healthy Hearts Project conducted from January 2008 to October 2009 in Turkey. We recorded serum level of biomarkers, including lipid profile, liver enzyme, paraoxonase, arylesterase and arginase to find their difference among the groups.
Results
Compared to the control group, gamma-glutamyl transferase (GGT) and arginase levels increased, while paraoxonase and arylesterase activity and high-density lipoprotein–cholesterol levels were low in the patient groups (P<0.001). A negative correlation was observed between paraoxonase and arylesterase activity and MetS.
Conclusion
We believe that the combined use of biomarkers, including GGT, arginase, paraoxonase, and arylesterase, may be useful in predicting diseases such as MetS and CVDs.

Keyword

Arginase; Cardiovascular diseases; Metabolic syndrome